{"entity":{"id":"nct05827614","kind":"trial","name":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","aka":[],"tldr":"A phase 1 trial of BBI-355 run by Boundless Bio, Inc., terminated.","summary":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications is a phase 1 interventional study registered as NCT05827614 by Boundless Bio, Inc., with 85 participants enrolled, started 2023-03-24. Conditions recorded: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic and Small Cell Lung Cancer. Interventions recorded: BBI-355, Erlotinib, Futibatinib and BBI-825.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05827614","url":"https://clinicaltrials.gov/study/NCT05827614"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","ovarian","endometrial","head-and-neck","cutaneous-scc","cervical","breast-cancer","sarcoma","undifferentiated-pleomorphic-sarcoma","metastatic-cancer","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["bbi-355","bbi-825"],"companies":["boundless-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05827614","phase":"1","setting":"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications","sponsor":"Boundless Bio, Inc.","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05827614/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/"}],"drug":[{"id":"bbi-355","kind":"drug","name":"BBI-355","route":"/drugs/bbi-355/"},{"id":"bbi-825","kind":"drug","name":"BBI-825","route":"/drugs/bbi-825/"}],"company":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/"}]}}